Droves of wellness enthusiasts, biohackers, social-media influencers, and celebrities are injecting experimental “anti-aging” ...

The FDA's approval of the new dosing option for Omlyclo addresses the diverse needs of patients with allergic and inflammatory conditions. "The approval of the additional 300 mg presentation of Omlyco ...

Add Yahoo as a preferred source to see more of our stories on Google. Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly ...

BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to ...

A new allergy medication is prompting clinicians to adjust their approach to oral food challenges — medically supervised tests in which clinicians give increasing doses of an allergen like peanut or ...

It’s not known whether Xolair (omalizumab) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether ...

Automakers have long touted the benefits of fuel injection, claiming increased efficiency and power. But as more cars have the system installed (around 73% in 2023), more and more consumers are ...

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines ...

Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...